Skip to main content
TipRanks
Go Ultimate75% OFF

Lotus Eye Hospital And Institute Ltd (LOTUSEYE) AI Stock Analysis

0 Followers
IN:LOTUSEYE

Lotus Eye Hospital And Institute Ltd

(NSE:LOTUSEYE)

Select Model
Rating:43.6Neutral
Price Target:INR 98.00â–¼(-5.45% Downside)
Action:reiterated
Date:09/12/26

The score is primarily held back by weak financial performance—sharp margin deterioration, rising leverage, and deeply negative free cash flow—despite continued revenue growth. Technicals are broadly neutral with negative MACD and the price below key longer-term moving averages. Valuation is a major headwind due to an extremely high P/E and no dividend yield provided.

Positive Factors
Steady Revenue GrowthContinued revenue expansion indicates that Lotus Eye Hospital is maintaining demand for its ophthalmology-focused consultations, diagnostics, procedures, and clinical services. Sustained top-line growth provides a foundation for future operating improvement if the company can convert additional volume into healthier margins.
Negative Factors
Severe Margin DeteriorationSharp deterioration in both net and operating margins means revenue growth is currently producing little or no operating profit. Persistently weak profitability would reduce reinvestment capacity, make earnings more vulnerable to cost pressure, and limit the financial benefits of further volume growth.

Lotus Eye Hospital And Institute Ltd (LOTUSEYE) vs. iShares MSCI India ETF (INDA)

-20%-10%0%10%20%30%40%IN:LOTUSEYE-1.33%INDA-4.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 2.12B
Dividend Yield
―
Average Volume (3M)
2,286
Price to Earnings (P/E)
444.6
Beta (1Y)
0.57
Revenue Growth
23.11%
EPS Growth
-29.81%
Country
India
Employees
402
Sector
Healthcare
Sector Strength
51
Industry
Medical - Care Facilities

Lotus Eye Hospital And Institute Ltd Business Overview & Revenue Model

Company Description

Lotus Eye Hospital and Institute Limited, a specialty eye care hospital, provides eye care and related services in India. The company offers ReLEx SMILE, a refractive lenticule extraction small incision lenticule extraction; touch free laser; lasik e...

Lotus Eye Hospital And Institute Ltd Financial Statement Overview

Summary

Revenue continues to grow (FY2026 up ~6.8% YoY), but profitability weakened sharply: net margin fell to ~0.15% and operating margin turned slightly negative (~-0.7%). Balance sheet leverage rose quickly (debt-to-equity ~0.26 vs ~0.06 prior year) and free cash flow swung deeply negative (~-106M), increasing funding and execution risk.

Income Statement

44Neutral

Balance Sheet

58Neutral

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue572.54M537.14M495.63M482.10M470.44M389.10M
Gross Profit145.80M102.25M100.41M135.66M121.38M192.53M
EBITDA55.97M45.55M47.44M79.42M88.37M68.09M
Net Income1.49M804.00K7.39M29.14M40.77M29.84M
Balance Sheet
Total Assets0825.97M695.74M666.27M631.88M615.97M
Cash, Cash Equivalents and Short-Term Investments38.27M37.26M39.78M69.30M83.31M87.93M
Total Debt0158.34M34.30M11.10M11.04M12.38M
Total Liabilities-601.38M224.60M95.73M72.17M56.09M69.88M
Stockholders Equity601.38M601.38M600.00M594.09M575.79M546.09M
Cash Flow
Free Cash Flow-2.68M-106.28M-21.25M403.00K12.90M-2.73M
Operating Cash Flow5.09M24.15M27.02M56.83M43.87M44.12M
Investing Cash Flow-4.83M-125.78M-43.50M-46.33M-21.94M-39.35M
Financing Cash Flow-9.27M98.39M-12.42M-34.02M-17.05M-15.75M

Lotus Eye Hospital And Institute Ltd Technical Analysis

Technical Analysis SentimentNegative
Last Price103.65

Price Trends

50DMA110.39Negative
100DMA114.11Negative
200DMA114.67Negative

Market Momentum

MACD-2.15Positive
RSI43.79Neutral
STOCH15.87Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LOTUSEYE, the sentiment is Negative. The current price of 103.65 is below the 20-day moving average (MA) of 106.82, below the 50-day MA of 110.39, and below the 200-day MA of 114.67, indicating a bearish trend. The MACD of -2.15 indicates Positive momentum. The RSI at 43.79 is Neutral, neither overbought nor oversold. The STOCH value of 15.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:LOTUSEYE.

Lotus Eye Hospital And Institute Ltd Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IN:LOTUSEYE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:MEDANTAIN:MEDANTA69NeutralINR 397.40B64.22―0.07%26.18%10.09%
IN:MAXHEALTHIN:MAXHEALTH63NeutralINR 1.01T73.39―0.19%15.17%1.63%
IN:APOLLOHOSPIN:APOLLOHOSP62NeutralINR 1.26T56.03―0.23%19.24%34.11%
IN:FORTISIN:FORTIS61NeutralINR 610.61B58.85―0.12%17.50%2.40%
IN:ASTERDMIN:ASTERDM55NeutralINR 644.56B102.25―0.54%50.47%10.73%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IN:LOTUSEYEIN:LOTUSEYE44NeutralINR 2.16B444.56――23.11%-29.81%

* Healthcare Sector Average

Performance Comparison

-20%0%20%IN:LOTUSEYEIN:APOLLOHOSPIN:ASTERDMIN:FORTISIN:MAXHEALTHIN:MEDANTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:LOTUSEYE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:LOTUSEYELotus Eye Hospital And Institute Ltd103.65-1.20-1.14%
IN:APOLLOHOSPApollo Hospitals Enterprise Limited8744.801370.2518.58%
IN:ASTERDMAster DM Healthcare Ltd.739.4589.5513.78%
IN:FORTISFortis Healthcare Ltd.808.80-111.27-12.09%
IN:MAXHEALTHMax Healthcare Institute Ltd1038.30-140.36-11.91%
IN:MEDANTAGlobal Health Limited1478.00252.0920.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 12, 2026